



DOCKET NO.: UNGR-1598

TECH 16
PATENT 9/3/2002
RECEIVED
9/3/2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Evan C. Unger, et al.

Serial No.: 09/699,679

Group Art Unit: 1617


Filed: October 30, 2000

Examiner: Michael A. Willis

For: **NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE**

I, S. Maurice Valla, Registration No. 43,966 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On August 14, 2002


S. Maurice Valla, Reg. No. 43,966

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

AMENDMENT

This is a response to an Office Action mailed on April 23, 2002. Please amend the application, without prejudice, as follows.

In the Claims:

Please cancel claims 36 to 53, without prejudice.

Please add the following new claims:

54. (Added) A compound according to Claim 1, wherein:

08/23/2002 AOSMANI 00000041 09699679

01 00:215

55.00 0P